CHUGAI-PHARMACEUTICAL
4.2.2019 02:02:14 CET | Business Wire | Press release
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that Roche has received notification that the EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Hemlibra® , a treatment for hemophilia A created by Chugai, for routine prophylaxis of bleeding episodes in adults and children with severe hemophilia A without factor VIII inhibitors, administered once weekly, every two weeks, or every four weeks. The CHMP has also adopted a positive opinion for additional dosing options of every two weeks or every four weeks in adults and children with hemophilia A with factor VIII inhibitors.
“We are thrilled that Hemlibra is expected to be approved shortly for people with severe hemophilia A without inhibitors in the Europe Union (EU). Also, I’m very pleased that people in the EU with hemophilia A will soon be offered multiple options of Hemlibra’s dosing interval regardless of their inhibitor expression,” said Chugai’s Executive Vice President, Co-Head of Project & Lifecycle Management Unit, Dr. Osamu Okuda. “Hemlibra is co-promoted by Chugai and Roche in Germany, France, and the United Kingdom, as is the case with the anti-rheumatic agent RoActemra® . We are committed to pursue our efforts in collaboration with Roche so that Hemlibra may further contribute to the treatment of hemophilia A.”
This positive opinion is based on results from two Phase III studies HAVEN 3 (NCT02847637) and HAVEN 4 (NCT03020160), conducted jointly with Roche and Genentech. HAVEN 3 study was conducted to evaluate the reduction of bleed rate of Hemlibra subcutaneous injection once a week and once every two weeks in people with hemophilia A (12 years of age or older) without inhibitors to factor VIII. HAVEN 4 study was conducted to evaluate efficacy, safety, and pharmacokinetics of Hemlibra subcutaneous injection every four weeks in people with hemophilia A (12 years of age or older), with and without inhibitors to factor VIII.
In Japan, Chugai obtained regulatory approval for Hemlibra from the Ministry of Health, Labour and Welfare in December 2018 for an additional indication of prophylactic treatment for people with hemophilia A without inhibitors to factor VIII, as well as for additional dosage and administration as a biweekly or every four-week treatment for people with hemophilia A with inhibitors to factor VIII.
References
Chugai’s HEMLIBRA®
Receives Regulatory Approval from U.S. FDA
for Hemophilia A without Inhibitors
Press release issued on October
5, 2018
https://www.chugai-pharm.co.jp/english/news/detail/20181005100000_553.html
Chugai’s HEMLIBRA®
Subcutaneous Injection Receives Approval
for Hemophilia A without Inhibitors and Extension of Dosing Interval --
HEMLIBRA is now available for Hemophilia A, regardless of inhibitor
status –
Press release issued on December 21, 2018
https://www.chugai-pharm.co.jp/english/news/detail/20181221153002_580.html
About Severe Hemophilia A
People with severe hemophilia A is defined as the condition with less than 1 % of factor VIII levels. Hemophilia A affects around 320,000 people worldwide, 1,2 approximately 50-60% of whom are expected to have a severe form of the disorder3 .
1) WFH. Guidelines for the management of haemophilia. 2012 [Internet;
cited 2018 July]. Available from:
http://www1.wfh.org/publications/files/pdf-1472.pdf
.
(as of February 1, 2019)
2) Berntorp E, Shapiro AD. Modern
haemophilia care. The Lancet 2012; 370:1447-1456.
3) Marder VJ, et
al. Hemostasis and Thrombosis. Basic Principles and Clinical Practice.
6th Edition, 2013. Milwakee, Wisconsin. Lippincott Williams and Wilkin.
About Chugai
Chugai Pharmaceutical is one of Japan’s leading research-based
pharmaceutical companies with strengths in biotechnology products.
Chugai, based in Tokyo, specializes in prescription pharmaceuticals and
is listed on the 1st section of the Tokyo Stock Exchange. As an
important member of the Roche Group, Chugai is actively involved in R&D
activities in Japan and abroad. Specifically, Chugai is working to
develop innovative products which may satisfy the unmet medical needs,
mainly focusing on the oncology area.
Additional information is
available on the internet at https://www.chugai-pharm.co.jp/english
.
Trademarks used or mentioned in this release are protected by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190203005041/en/
Contact:
For Media Chugai Pharmaceutical Co., Ltd. Media Relations Group, Corporate Communications Dept., Tomoko Shimizu Tel: +81-3-3273-0881 E-mail: pr@chugai-pharm.co.jp
For US media Chugai Pharma USA Inc. Casey Astringer Tel: +1-908-516-1350 E-mail: pr@chugai-pharm.com
For European media Chugai Pharma France SAS Nathalie Leroy Tel: +33-1-56-37-05-21 E-mail: pr@chugai.eu
For Taiwanese media Chugai Pharma Taiwan Ltd. Susan Chou Tel: +886-2-2715-2000 E-mail: pr@chugai.com.tw
For Investors Chugai Pharmaceutical Co., Ltd. Investor Relations Group, Corporate Communications Dept., Toshiya Sasai Tel: +81-3-3273-0554 E-mail: ir@chugai-pharm.co.jp
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ViTAA Medical and The Society for Vascular Surgery Announce Strategic Partnership20.11.2026 15:00:00 CET | Press release
ViTAA Medical to Become Key SVS AI Partner, Advancing AI Education and Responsible Adoption in Vascular Care ViTAA Medical Solutions Inc. (ViTAA) today announced a strategic partnership with The Society for Vascular Surgery (SVS) to advance evidence, education, and the responsible adoption of quantitative imaging and artificial intelligence in vascular care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120954362/en/ The partnership will support evidence building, best practices, educational resources for SVS members, physicians and trainees on AI validation, interpretation, and clinical limitations. The relationship has the potential to pave the way for additional AI tools and resources for SVS members through the Society in the future. The partnership creates a framework for the organizations to lead AI-enabled research opportunities involving imaging and clinical outcomes. Mitchel Benovoy, PhD, Chief Executive Officer
Epitech Group and Horus Pharma sign a global licensing agreement to develop adelmidrol in eye health20.11.2026 14:39:00 CET | Press release
Epitech Group S.p.A., an Italian biopharmaceutical firm specializing in neuro-inflammation, and Horus Pharma, a French laboratory specializing in ophthalmology, announce a global licensing agreement for adelmidrol, a molecule belonging to the ALIAmide family, developed by Epitech Group. This agreement grants Horus Pharma exclusive rights to develop and market adelmidrol for human ophthalmology and periocular dermatology applications. It aims to explore new approaches to address unmet medical needs in eye health. A combination of complementary scientific expertise Epitech Group has been studying ALIAmides and their role in physiological regulatory mechanisms for over 30 years, building on the research of Rita Levi-Montalcini, the 1986 Nobel Prize in Medicine laureate who first identified the ALIA mechanism. Horus Pharma, for its part, contributes over 20 years of ophthalmology expertise, strong R&D capabilities, and its international presence. Against the backdrop of an aging population
Adyen Merchants Can Now Offer Klarna in AI Agent Checkout20.11.2026 14:30:00 CET | Press release
Klarna is Adyen’s first non-card, local payment method for agentic commerce Klarna (NYSE: KLAR), the everyday finance network, and Adyen (AMS: ADYEN) today announced that shoppers can now pay with Klarna when an AI agent checks out for them through Adyen Agentic. Klarna is the first payment option beyond cards available in Adyen Agentic, Adyen’s agentic commerce suite, and merchants that already offer Klarna through Adyen can switch it on with no new integration work. Today, most AI shopping agents complete purchases with a stored credit or debit card, leaving out flexible payment options that many shoppers choose at regular checkout. With Klarna now a payment method within Adyen Agentic, the agent shows shoppers the same Klarna options the merchant already offers, such as paying in full, in interest-free installments or with financing. Shoppers review and confirm every purchase before it is completed. Adyen built the integration on Klarna’s open payment handler, a published specificat
SatSure Raises Series B to Scale Its Full-Stack Earth Intelligence Platform for Global Markets20.11.2026 11:05:00 CET | Press release
India’s sovereign space-technology fund leads the first close of the ongoing INR 200 crore (c. USD 21 million) round SatSure, a global Earth intelligence company headquartered in India, today announced the first close of its ongoing INR 200 crore (c. USD 21 million) Series B round. The round is led by a INR 60 crore (c. USD 6.4 million) investment from the Antariksh Venture Capital Fund (AVCF), India’s sovereign space-technology fund, anchored by the national space regulator IN-SPACe and managed by SIDBI Venture Capital Limited. The investment marks AVCF’s first deployment into the downstream data and AI layer of India’s space economy, extending the fund beyond upstream launch and satellite hardware into commercial space-data infrastructure capable of serving global enterprise and sovereign markets. The round comprises INR 165 crore (c. USD 17.6 million) in equity, INR 25 crore (c. USD 2.7 million) in venture debt and INR 10 crore (c. USD 1.1 million) in secondary transactions, closing
Al Shera’a, DEWA’s Headquarters, Wins First Place in the YeS Honor Awards at the COP31 International Sustainable Buildings Competition20.11.2026 10:16:00 CET | Press release
In a new achievement that underscores Dubai’s pioneering position in smart and sustainable buildings, Al Shera’a, the headquarters of Dubai Electricity and Water Authority (DEWA), has won the first place in the YeS Honor Award–Sustainable Design category, in the COP31 International Sustainable Buildings Competition. The award was launched by the COP31 Presidency with the support of the Global Alliance for Buildings and Construction, hosted by the United Nations Environment Programme, during COP31 in Antalya, Türkiye. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118255551/en/ HE Saeed Mohammed Al Tayer, MD&CEO of DEWA, received the award in the presence of HE Amna bint Abdullah Al Dahak, UAE Minister of Climate Change and Environment, from HE Hasan Suver, Deputy Minister of Environment, Urbanisation and Climate Change of the Republic of Türkiye, representing the COP31 Presidency. The competition attracted more than 1,000
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
